At TechCrunch Disrupt in October 2026, Science Corporation CEO Max Hodak announced the company had implanted its PRIMA vision-restoring chip into the first Stargardt disease patient, who received the implant at Sydney Eye Hospital in Australia in May. Hodak described retinal prostheses as a type of brain-computer interface and outlined plans to expand BCI technology to broader medical applications. PRIMA is already commercially available in Europe for geographic atrophy patients.